Baclofen intravenous - Allaysis

Drug Profile

Baclofen intravenous - Allaysis

Alternative Names: ALL 1401

Latest Information Update: 19 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Allaysis
  • Class Aminobutyric acids; Antispastics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Muscle spasticity

Most Recent Events

  • 19 May 2016 Chemical structure information added
  • 03 May 2016 Allaysis and University of Minnesota - Clinical and Translational Science Institute plan a phase I/II trial in Healthy volunteers in USA (IV) (NCT02760992)
  • 26 Feb 2016 Preclinical trials in Muscle spasticity in USA (IV) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top